<DOC>
	<DOCNO>NCT01502969</DOCNO>
	<brief_summary>This multiple-site phase 2b , randomize , placebo control study evaluate safety immunogenicity Rotavin-M1 , produce Center Research Production Vaccines Biologicals , Vietnam .</brief_summary>
	<brief_title>Safety Immunogenicity Assessment Rotavin-M1 Vietnamese Children</brief_title>
	<detailed_description>The investigator evaluate vaccine schedule consist 2 dos Rotavin-M1 , 10e6.3ffu/dose 2 month interval child two study site , Thanh Son- Phu Tho Thai Binh city-Thai Binh province . This vaccine dose schedule chosen base result previous dose-escalating study ( NCT01377571 ) .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<criteria>At study entry 1 . A healthy male female , 6 12 week age ( 42 day 84 day age ) . 2 . Full term gestation ( &gt; =37 week ) . 3 . Birth weight subject &gt; =2.5 kg . 4 . Healthy subject establish medical history clinical examination enter study . 5 . Did use dose Rota virus vaccine . 6 . Written inform consent obtain parent guardian subject . At dose 2 1 . Received dose 1 . 2 . Oral inform consent obtain parent guardian subject continue participate study . At study entry 1 . Has chronic disease ( cardiovascular , liver , kidney disease ) . 2 . Acute disease time enrolment . 3 . Administering corticosteroid ( &gt; 1mg/kg/day ) . 4 . Received immunosuppressive therapy within 4 week vaccination ( Administration immunoglobulins and/or blood product corticosteroid &gt; 2 week ) . 5 . Immunosuppressive immunodeficient condition . 6 . Family immunosuppressive immunodeficient condition medical history . 7 . History high fever convulsion . 8 . Allergic reaction component vaccine , include anaphylactic shock antibiotic . 9 . Preterm gestation delivery ( gestation period &lt; 37 week ) . 10 . Low birth weight ( &lt; 2.5 kg ) . 11 . Fever ( axillary temperature &gt; 38oC ) within 3 day day vaccination . 12 . Malnutrition . 13 . Has type blood disorder , leukemia , malignant tumor affect bone marrow lymph system . 14 . Use investigational nonregistered product ( unlicensed drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . At dose 2 1 . Acute disease time 2nd dose . 2 . Administering corticosteroid ( &gt; 1mg/kg/day ) . 3 . Received immunosuppressive therapy within 4 week vaccination ( Administration immunoglobulins and/or blood product corticosteroid &gt; 2 week ) . 4 . History allergic disease reaction likely exacerbate component study vaccine . 5 . Fever ( axillary temperature &gt; 38oC ) within 3 day day vaccination . 6 . Has type blood disorder , leukemia , malignant tumor affect bone marrow lymph system . 7 . Use investigational nonregistered product ( unlicensed drug vaccine ) study vaccine study period .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>diarrhea</keyword>
	<keyword>fever</keyword>
	<keyword>nausea</keyword>
	<keyword>vomit</keyword>
	<keyword>irritability</keyword>
</DOC>